Billionaire Profile
Wolfgang Marguerre & family
Global Rank
#568

Image: Public domain | via Wikimedia Commons

Wolfgang Marguerre & family

CEO, Octapharma
DE
Real-Time Net Worth
$6.6B
As of December 2025
Age
84
Source
Pharmaceuticals
Industry
healthcare
Citizenship
DE

Biography

Wolfgang Marguerre, born in 1941, is a German billionaire businessman and the chairman and owner of the Octapharma Group. His wealth stems from pharmaceuticals, with Octapharma being a leading manufacturer of blood plasma products. Marguerre co-founded Octapharma in 1983, and under his leadership, the company has grown into a global healthcare provider with operations in over 120 countries. He is known for his significant contributions to philanthropy, particularly in supporting children with bleeding disorders and promoting the arts. Marguerre's career includes managerial positions in various pharmaceutical companies before establishing Octapharma. His dedication to innovation and patient care has solidified his position as a prominent figure in the healthcare industry.

Wealth Over Time

In-Depth Profile

Early Life

Wolfgang Marguerre was born in Heidelberg, Germany, in 1941. He was raised and educated in Heidelberg, studying Political and Economic Science at Heidelberg University. He later pursued an MBA at INSEAD in 1972.

Rise to Success

Before founding Octapharma in 1983, Marguerre held several managerial positions in pharmaceutical companies, including Pharmaplast, Baxter-Travenol Europe, and Revlon Healthcare Group. In 1983, he co-founded Octapharma with Robert Taub. Under Marguerre's leadership, Octapharma has become a leading manufacturer of medicines derived from human proteins, specializing in treatments for hematology, immunology, intensive care, and emergency medicine. The company has a global presence, with products available in 120 countries and reaching hundreds of thousands of patients annually.

Key Business Strategies

Octapharma's success is attributed to its focus on human protein-based therapies, derived from human plasma and human cell lines. The company has invested heavily in research and development and has seven R&D sites and five state-of-the-art manufacturing facilities. Octapharma sources its plasma from its own donation centers and external sources. The company continues to expand its production and enhance its portfolio in adjacent areas, aiming for long-term sustainable growth.

Philanthropy

Marguerre is actively involved in philanthropy, supporting various causes. He has donated significantly to renovate the Heidelberg Theater and integrate refugees in Heidelberg. He is a sponsor of 70 children with bleeding disorders in India, Nepal, Romania, and the Philippines through Octapharma's corporate sponsorship of Save One Life.

Career Milestones

1972

MBA

Completed MBA at INSEAD.

1983

Co-founded Octapharma

Co-founded Octapharma with Robert Taub.

2009

Legion of Honour

Awarded the Légion d'honneur by France.

2011

Gold Decoration of Honour

Awarded the Gold Decoration of Honour for Services to the Republic of Austria.

Philanthropy & Social Impact

Arts

Theater Heidelberg Renovation

$17.5M

Donation for the renovation of the Heidelberg Theater

Social Welfare

Refugee Integration in Heidelberg

$1.13M

Donation to accept and integrate refugees in Heidelberg

Healthcare

Save One Life

Undisclosed

Sponsors 70 children with bleeding disorders

Education

Octapharma Scholarship & Chair in Decision Neuroscience

Undisclosed

Supporting education through INSEAD

Business Philosophy & Leadership

Notable Quotes

"We must never allow ourselves to become complacent, or to think that we have achieved "enough.""

Leadership Principles

Commitment to Patient Care

Dedication to providing innovative healthcare solutions and advancing human life.

Family Ownership

Maintaining a long-term vision and commitment to patients and responsible value creation.

Innovation

Strengthening commitment to hematology, immunology and critical care by enhancing and expanding the portfolio into new indications.

Accessibility

Expanding accessibility of therapies to more patients around the world.